Business
CytoSorb® is Approved and Available for the Removal of Ticagrelor, a Leading Anti-Platelet Drug, During Cardiopulmonary Bypass in the E.U.
CytoSorb is the only approved therapy to remove ticagrelor in the European Union, and is intended to address a major unmet medical need of potentially
About this update from Cytosorbents Corporation
[{"type":"text","content":"CytoSorb is the only approved therapy to remove ticagrelor in the European Union, and is intended to address a major unmet medical need of potentially life-threatening postoperative bleeding in cardiothoracic surgery patients on the drug\n\n\nMONMOUTH JUNCTION, N.J., Jan. 29, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a critical care immunotherapy leader specializing in blood purification, announces that CytoSorb® is now approved and immediately available for the removal of the anti-platelet agent, ticagrelor, during surgery requiring cardiopulmonary bypass (CPB), with the achievement of European Union regulatory approval and CE Mark label expansion for this indication. \n\n \n \n\n \nTicagrelor (Astra Zeneca - Brilinta®, Brilique®) is one of the most commonly used anti-platelet drugs to reduce the risk of cardiac death, heart attacks, and strokes in patients with either a history of a heart attack, or those actively undergoing percutaneous coronary intervention (PCI) with stent placement for acute coronary syndrome or heart attack. However, in patients on the drug requiring urgent or emergent coronary artery bypass graft (CABG) surgery or other cardiothoracic surgery procedure, the risk of major fatal/life-threatening bleeding has been reported to be as high as 65%. CytoSorb rapidly removes ticagrelor from blood. The use of CytoSorb during emergency cardiac surgery significantly reduced post-operative bleeding complications in a landmark observational study and had projected cost savings of approximately $5,000 per patient, including the cost of the device.\nMr. Vincent Capponi, Chief Operating Officer of CytoSorbents stated, \"CytoSorb is the only approved therapy to remove ticagrelor in the European Union and in all 58 countries where CytoSorb is distributed. Cardiothoracic surgeons in these territories can now use CytoSorb on-label during surgery involving cardiopulmonary bypass, to rapidly remove ticagrelor from the body in 1-2 hours, as compared to 3-7 days with natural clearance, with the intent to reduce perioperative bleeding complications caused by this potent anti-platelet agent, while restoring natural hemostasis. CytoSorb is easily installed into a side circuit of the heart-lung machine during cardiopulmonary bypass, and has been used safely in thousands of cardiac surgeries for other reasons to da...